| Literature DB >> 32589537 |
Lisa Amani1, Rabia Warraich1, Nishil Patel2, Hasan Tahir3,4.
Abstract
Rheumatology patients who are taking immunosuppressants are considered to be at 'high risk' from COVID-19, hence have been self-isolating or shielding. However, they may be protected from the features of hyperinflammation driven by a 'cytokine storm', so may have better clinical outcomes if infected. This editorial discusses whether it may not be necessary to advise these patients to shield.Entities:
Mesh：
Substances：
Year: 2020 PMID： 32589537 DOI： 10.12968/hmed.2020.0284
Source DB: PubMed Journal: Br J Hosp Med (Lond) ISSN： 1750-8460 Impact factor: 0.825